Sino Biopharm Licenses COPD Drug TQC3721 Overseas Rights to AstraZeneca for Up to $1.9 Billion
2026-07-09 03:55:34
Sino Biopharmaceutical said it has licensed the overseas rights to its self-developed COPD drug candidate TQC3721 (a PDE3/4 inhibitor) to AstraZeneca for total consideration of up to $1.9 billion, marking the company’s second major business development deal this year, according to Jiemian News. As of 10:59 a.m. on July 9, 2026, the CSI Hong Kong Stock Connect Innovative Drug Index was up 1.22%, with Insilico Medicine rising 6.92%, WuXi Biologics up 4.71% and Sino Biopharmaceutical up 3.73%. Separately, data cited in the report showed that as of June 30, 2026, the index’s top 10 constituents accounted for 70.81% of its weight.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
